—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...

A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need ...

—A team of researchers in Tokyo recently took on the challenge of attempting to determine whether comprehensive genomic profiling has clinical utility in a large cohort of patients with non-small cell ...

The National Comprehensive Cancer Network’s newly updated non-small cell lung cancer guideline adds sevabertinib as a treatment option for some patients with advanced disease, makes datopotamab ...

There has been a therapeutic revolution in lung cancer. According to the American Lung Association, survival increased by 26% between 2019 and 2024. This progress is largely driven by emerging ...

Validated companion diagnostic offers rapid results and supports eligible patient selection for newly approved targeted therapy FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NEO), a leading ...

Experts explore HER2 mutations and the critical role of comprehensive molecular profiling in optimizing treatment for non-small cell lung cancer patients. Stay ahead of policy, cost, and ...

A panel held during the Institute for Value-Based Medicine event in Chicago on August 14, 2025, included discussions of access to biomarker testing and perioperative treatment in patients with ...

“It's My Wish, We Need This Program”: Qualitative Reflections From People With High-Grade Brain Cancer Consenting to Postmortem Brain Donation Targeted therapy has transformed treatment of non–small ...

Identification of a specific genetic mutation in patients with non-small-cell lung cancer (NSCLC) helps clinicians select the best treatment option. Potential NSCLC patients usually undergo invasive ...